Novel treatment modalities for nonalcoholic steatohepatitis

Sanjaya Satapathy, Arun J. Sanyal

Research output: Contribution to journalReview article

37 Citations (Scopus)

Abstract

Nonalcoholic steatohepatitis (NASH) is the most common cause of chronic liver disease in the Western world. It can lead to cirrhosis and hepatocellular cancer, and is independently associated with an increased risk of death due to cardiovascular and liver diseases. Over the past 5 years, numerous advances in understanding its pathogenesis have been made, providing a rationale for translation of this information into clinical trials. Although the optimum therapy is still awaited, there is strong evidence to support the use of vitamin E in selected subjects. Many other potential therapeutic options are now available. In this paper, we review the status of both current and emerging therapeutic strategies for patients with NASH.

Original languageEnglish (US)
Pages (from-to)668-675
Number of pages8
JournalTrends in Endocrinology and Metabolism
Volume21
Issue number11
DOIs
StatePublished - Nov 1 2010

Fingerprint

Liver Diseases
Western World
Liver Neoplasms
Vitamin E
Fibrosis
Chronic Disease
Cardiovascular Diseases
Therapeutics
Clinical Trials
Non-alcoholic Fatty Liver Disease

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Novel treatment modalities for nonalcoholic steatohepatitis. / Satapathy, Sanjaya; Sanyal, Arun J.

In: Trends in Endocrinology and Metabolism, Vol. 21, No. 11, 01.11.2010, p. 668-675.

Research output: Contribution to journalReview article

@article{789e9d2700954f08b9e99ead6b336807,
title = "Novel treatment modalities for nonalcoholic steatohepatitis",
abstract = "Nonalcoholic steatohepatitis (NASH) is the most common cause of chronic liver disease in the Western world. It can lead to cirrhosis and hepatocellular cancer, and is independently associated with an increased risk of death due to cardiovascular and liver diseases. Over the past 5 years, numerous advances in understanding its pathogenesis have been made, providing a rationale for translation of this information into clinical trials. Although the optimum therapy is still awaited, there is strong evidence to support the use of vitamin E in selected subjects. Many other potential therapeutic options are now available. In this paper, we review the status of both current and emerging therapeutic strategies for patients with NASH.",
author = "Sanjaya Satapathy and Sanyal, {Arun J.}",
year = "2010",
month = "11",
day = "1",
doi = "10.1016/j.tem.2010.08.003",
language = "English (US)",
volume = "21",
pages = "668--675",
journal = "Trends in Endocrinology and Metabolism",
issn = "1043-2760",
publisher = "Elsevier Inc.",
number = "11",

}

TY - JOUR

T1 - Novel treatment modalities for nonalcoholic steatohepatitis

AU - Satapathy, Sanjaya

AU - Sanyal, Arun J.

PY - 2010/11/1

Y1 - 2010/11/1

N2 - Nonalcoholic steatohepatitis (NASH) is the most common cause of chronic liver disease in the Western world. It can lead to cirrhosis and hepatocellular cancer, and is independently associated with an increased risk of death due to cardiovascular and liver diseases. Over the past 5 years, numerous advances in understanding its pathogenesis have been made, providing a rationale for translation of this information into clinical trials. Although the optimum therapy is still awaited, there is strong evidence to support the use of vitamin E in selected subjects. Many other potential therapeutic options are now available. In this paper, we review the status of both current and emerging therapeutic strategies for patients with NASH.

AB - Nonalcoholic steatohepatitis (NASH) is the most common cause of chronic liver disease in the Western world. It can lead to cirrhosis and hepatocellular cancer, and is independently associated with an increased risk of death due to cardiovascular and liver diseases. Over the past 5 years, numerous advances in understanding its pathogenesis have been made, providing a rationale for translation of this information into clinical trials. Although the optimum therapy is still awaited, there is strong evidence to support the use of vitamin E in selected subjects. Many other potential therapeutic options are now available. In this paper, we review the status of both current and emerging therapeutic strategies for patients with NASH.

UR - http://www.scopus.com/inward/record.url?scp=78049243953&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78049243953&partnerID=8YFLogxK

U2 - 10.1016/j.tem.2010.08.003

DO - 10.1016/j.tem.2010.08.003

M3 - Review article

VL - 21

SP - 668

EP - 675

JO - Trends in Endocrinology and Metabolism

JF - Trends in Endocrinology and Metabolism

SN - 1043-2760

IS - 11

ER -